Literature DB >> 31816368

Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.

Darshan Singh1, Nelson Jeng Yeou Chear2, Suresh Narayanan3, Francisco Leon4, Abhisheak Sharma5, Christopher R McCurdy4, Bonnie A Avery5, Vicknasingam Balasingam2.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Kratom (Mitragyna speciosa) is a native medicinal plant of Southeast Asia widely reported to be used to reduce opioid dependence and mitigate withdrawal symptoms. There is also evidence to suggest that opioid poly-drug users were using kratom to abstain from opioids. AIM OF THE STUDY: To determine the patterns and reasons for kratom use among current and former opioid poly-drug users in Malaysia.
MATERIALS AND METHODS: A total of 204 opioid poly-drug users (142 current users vs. 62 former users) with current kratom use history were enrolled into this cross-sectional study. A validated UPLC-MS/MS method was used to evaluate the alkaloid content of a kratom street sample.
RESULTS: Results from Chi-square analysis showed that there were no significant differences in demographic characteristics between current and former opioid poly-drug users except with respect to marital status. Current users had higher odds of being single (OR: 2.2: 95%CI: 1.21-4.11; p < 0.009). Similarly, there were no significant differences in the duration (OR: 1.1: 0.62-2.03; p < 0.708), daily quantity (OR: 1.5: 0.85-2.82; p < 0.154) or frequency of kratom use between current and former opioid poly-drug users (OR: 1.1: 0.62-2.06; p < 0.680). While both current and former opioid users reported using kratom to ameliorate opioid withdrawal, current users had significantly higher likelihood of using kratom for that purpose (OR: 5.4: 95%CI: 2.81-10.18; p < 0.0001). In contrast, former opioid users were more likely to be using kratom for its euphoric (mood elevating) effects (OR: 1.9: 95%CI: 1.04-3.50; p < 0.035). Results from the UPLC-MS/MS analysis indicated the major alkaloids present in the representative kratom street sample (of approximately 300 mL of brewed kratom) were mitragynine, followed by paynantheine, speciociliatine and speciogynine, as well as low levels of 7-hydroxymitragynine.
CONCLUSIONS: Both current and former opioid poly-drug users regularly used kratom (three glasses or about 900 mL daily or the equivalent of 170.19 mg of mitragynine) to overcome opioid poly-drug use problems.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kratom; Malaysia; Mitragynine; Opioid poly-drug users

Mesh:

Substances:

Year:  2019        PMID: 31816368     DOI: 10.1016/j.jep.2019.112462

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  19 in total

1.  The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.

Authors:  Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Michelle A Kuntz; Alexandria S Senetra; Marco Mottinelli; Francisco León; Luis F Restrepo; Avi Patel; Nicholas P Ho; Takato Hiranita; Abhisheak Sharma; Lance R McMahon; Christopher R McCurdy
Journal:  Drug Metab Dispos       Date:  2021-11-10       Impact factor: 3.922

2.  Metabolism of Speciociliatine, an Overlooked Kratom Alkaloid for its Potential Pharmacological Effects.

Authors:  Shyam H Kamble; Erin C Berthold; Siva Rama Raju Kanumuri; Tamara I King; Michelle A Kuntz; Francisco León; Marco Mottinelli; Lance R McMahon; Christopher R McCurdy; Abhisheak Sharma
Journal:  AAPS J       Date:  2022-07-19       Impact factor: 3.603

3.  Activity of Mitragyna speciosa ("Kratom") Alkaloids at Serotonin Receptors.

Authors:  Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2021-09-01       Impact factor: 8.039

4.  Pharmacokinetics and Safety of Mitragynine in Beagle Dogs.

Authors:  Elizabeth A Maxwell; Tamara I King; Shyam H Kamble; Kanumuri Siva Rama Raju; Erin C Berthold; Francisco León; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy; Abhisheak Sharma
Journal:  Planta Med       Date:  2020-07-21       Impact factor: 3.352

5.  Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.

Authors:  Shyam H Kamble; Erin C Berthold; Tamara I King; Siva Rama Raju Kanumuri; Raluca Popa; Julius R Herting; Francisco León; Abhisheak Sharma; Lance R McMahon; Bonnie A Avery; Christopher R McCurdy
Journal:  J Nat Prod       Date:  2021-02-23       Impact factor: 4.050

6.  Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample.

Authors:  Joseph J Palamar
Journal:  Am J Prev Med       Date:  2021-04-29       Impact factor: 6.604

7.  Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.

Authors:  Lisa L Wilson; Soumen Chakraborty; Shainnel O Eans; Thomas J Cirino; Heather M Stacy; Chloe A Simons; Rajendra Uprety; Susruta Majumdar; Jay P McLaughlin
Journal:  Cell Mol Neurobiol       Date:  2021-01-12       Impact factor: 4.231

8.  Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic - A case report.

Authors:  Elisabeth Müller; Thomas Hillemacher; Christian P Müller
Journal:  Heliyon       Date:  2021-05-10

9.  Accelerated Solvent Extractions (ASE) of Mitragyna speciosa Korth. (Kratom) Leaves: Evaluation of Its Cytotoxicity and Antinociceptive Activity.

Authors:  Yong Sean Goh; Thiruventhan Karunakaran; Vikneswaran Murugaiyah; Rameshkumar Santhanam; Mohamad Hafizi Abu Bakar; Surash Ramanathan
Journal:  Molecules       Date:  2021-06-17       Impact factor: 4.411

10.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.